{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:31:22Z","timestamp":1786649482239,"version":"build-2736575974"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Alzheimer\u2019s disease (AD), characterized by cognitive decline, lacked effective cures. Mesenchymal stem cell (MSC) factors (MSCFs) offered a new approach by promoting brain tissue repair and modulating immune responses, presenting a promising alternative to AD treatment with minimal risks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim:<\/jats:title>\n                    <jats:p>This study aimed to investigate the effects of MSCF on AD and to compare the effects with traditional MSC treatments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      Sixty patients were divided into control and observation groups, with 30 cases in each group. The control group were injected intravenously with 10 mL of MSCs (5.0 \u00d7 10\n                      <jats:sup>9<\/jats:sup>\n                      L\n                      <jats:sup>-1<\/jats:sup>\n                      ) plus 100 mL normal saline (once every 5 days for six consecutive treatments). The observation group received intramuscular injections of 0.5 mL (1 mL for the first dose) of MSCF (every other day for 15 consecutive treatments). Amyloid-\u03b2 42 (A\u03b242) and Tau protein concentrations in cerebrospinal fluid were determined by ELISA pretreatment and at 1, 3, and 6 months\u2019 post-treatment. The Clinical Dementia Rating of AD patients was recorded at these intervals to evaluate treatment efficacy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A\u03b242 levels increased, and Tau protein levels decreased in both groups. The CDR score dropped post treatment. The total effective rate and clinical cure rate were 86.67% and 6.70% in the control group and 100% and 40% in the observation group, respectively. MSCF and MSCs uniquely impact AD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>MSCs contributed to damaged nerve cell repair, new nerve cell differentiation, and the participation of some dormant nerve cells in physiological activity. MSCF offered a small-dose, rapid, and safe treatment with simple operation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/njcp.njcp_561_24","type":"journal-article","created":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T23:00:34Z","timestamp":1730329234000},"page":"1216-1220","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Clinical Study on Mesenchymal Stem Cell Factors Therapy for Alzheimer\u2019s Disease"],"prefix":"10.4103","volume":"27","author":[{"given":"P","family":"Xie","sequence":"first","affiliation":[{"name":"Research and Development Center of Guangdong New Journey Life Sciences, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Unit 32265, PLA Hospital, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Li","sequence":"additional","affiliation":[{"name":"Research and Development Center of Guangdong New Journey Life Sciences, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Deng","sequence":"additional","affiliation":[{"name":"Research and Development Center of Guangdong New Journey Life Sciences, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Music Education, Xinghai Conservatory of Music, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,10,30]]},"reference":[{"key":"R1-20260427","first-page":"36","article-title":"Progress in the pathogenesis and treatment of Alzheimer\u2019s disease","volume":"10","author":"Liu","year":"2020","journal-title":"NeuroPharmacol"},{"key":"R2-20260427","first-page":"2116","article-title":"Progress in the clinical transformation of human embryonic stem cells","volume":"40","author":"Wu","year":"2018","journal-title":"Chin J Cell Biol"},{"key":"R3-20260427","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1002\/jcp.27182","article-title":"Stem cell-based therapy for Parkinson\u2019s disease with a focus on human endometrium-derived mesenchymal stem cells","volume":"234","author":"Bagheri-Mohammadi","year":"2019","journal-title":"J Cell Physiol"},{"key":"R4-20260427","first-page":"138","article-title":"Classification and diagnostic criteria for functional neurological diseases","volume":"23","author":"Wang","year":"2023","journal-title":"Chin J Modern Neurol Dis"},{"key":"R5-20260427","first-page":"6","article-title":"Umbilical cord mesenchymal stem cell transplantation for ischemic heart disease patients at a 3-year follow-up","volume":"25","author":"Jing","year":"2021","journal-title":"Chin Tissue Engin Res"},{"key":"R6-20260427","first-page":"2716","article-title":"Alzheimer\u2019s disease cell therapy","volume":"41","author":"Cheng","year":"2020","journal-title":"J Qiqihar Med Coll"},{"key":"R7-20260427","first-page":"50","article-title":"Experimental study of embryin prevention and treatment of Alzheimer\u2019s disease","volume":"14","author":"Xie","year":"2023","journal-title":"Chin Sci Technol J Database Med Health"},{"key":"R8-20260427","first-page":"39","article-title":"Progress in studying the pathogenesis of Alzheimer\u2019s disease","volume":"20","author":"Li","year":"2020","journal-title":"World\u2019s Latest Med Inform Abst"},{"key":"R9-20260427","first-page":"257","article-title":"Mechanism of therapeutic action of mesenchymal stem cell transplantation","volume":"8","author":"Wang","year":"2019","journal-title":"J Transl Med"},{"key":"R10-20260427","first-page":"247","article-title":"Research progress on mesenchymal stem cell exosomes in the treatment of Alzheimer\u2019s disease","volume":"9","author":"Jin","year":"2019","journal-title":"Chin J Cell Stem Cells"},{"key":"R11-20260427","doi-asserted-by":"crossref","first-page":"679","DOI":"10.2174\/1570159X18666200807130637","article-title":"Das S, Joseph A, Shenoy GG, Alex AT, Mudgal J. Neurodegenerative pathways in Alzheimer\u2019s disease: A review","volume":"19","author":"Ramachandran","year":"2021","journal-title":"Curr Neuropharmacol"},{"key":"R12-20260427","doi-asserted-by":"crossref","first-page":"210","DOI":"10.2174\/1874467213666200602133032","article-title":"Apelin\/Apelin receptor system: Molecular characteristics, physiological roles, and prospects as a target for disease prevention and pharmacotherapy","volume":"14","author":"Kinjo","year":"2021","journal-title":"Curr Mol Pharmacol"},{"key":"R13-20260427","first-page":"227","article-title":"Mesenchymal stem cells and the neuronal microenvironment in the area of spinal cord injury","volume":"014","author":"Mukhamedshina","year":"2019","journal-title":"NevraS Regev Res"},{"key":"R14-20260427","first-page":"38","article-title":"Preliminary study on the efficacy of small molecule peptide LK-5 in mice with liver fibrosis","volume":"30","author":"Liao","year":"2021","journal-title":"Chin Ethnic Folk Med"},{"key":"R15-20260427","first-page":"186","article-title":"Progress in the neuroprotective effects and mechanism of glucagon-like peptide 1 analogues on Alzheimer\u2019s disease","volume":"43","author":"Mei","year":"2023","journal-title":"Lab Anim Compar Med"}],"container-title":["Nigerian Journal of Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/njcp.njcp_561_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T18:54:41Z","timestamp":1786647281000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/njcp.njcp_561_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":15,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/njcp.njcp_561_24","relation":{},"ISSN":["1119-3077","2229-7731"],"issn-type":[{"value":"1119-3077","type":"print"},{"value":"2229-7731","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"2024-08-27","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-08","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}